Combination of Targeted Therapies for Colorectal Cancer Treatment

Area of Science:

• Oncology
• Pharmacology
• Drug Delivery

Background:

• Developing selective tumor-destructive therapies is a major challenge in cancer treatment.
• Targeted therapies like bevacizumab (Bev) and cytotoxic payloads such as monomethyl auristatin E (MMAE) are crucial in modern oncology.

Purpose of the Study:

• To evaluate the efficacy of combining bevacizumab (Bev) with a novel β-glucuronidase-responsive albumin-binding prodrug of MMAE (MMAE prodrug) for colorectal cancer treatment.
• To compare this novel combination therapy against the standard FOLFOX and Bev regimen in a preclinical model.

Main Methods:

• Treatment of mice with colorectal cancer xenografts using the combined Bev and MMAE prodrug therapy.
• Assessment of therapeutic activity and comparison with FOLFOX and Bev combination therapy.
• Investigation of the underlying synergistic or additive effects between Bev and the selectively released MMAE.

Main Results:

• The combination of Bev and the MMAE prodrug demonstrated superior therapeutic activity against implanted colorectal cancer in mice.
• This novel combination outperformed the established FOLFOX and Bev treatment regimen.
• The enhanced efficacy is attributed to synergistic or additive effects between Bev and MMAE, released specifically within the tumor microenvironment.

Conclusions:

• Bevacizumab combined with a β-glucuronidase-responsive MMAE prodrug offers a highly effective strategy for colorectal cancer treatment.
• This approach may significantly improve the therapeutic index of MMAE-based drug delivery systems, including antibody-drug conjugates.
• The findings suggest a promising new therapeutic avenue for colorectal cancer and potentially other malignancies utilizing MMAE payloads.